NEW YORK (360Dx) – With additional data on the performance of its Videssa Breast proteomic breast cancer assay out this week, Provista Diagnostics is now prepping a new study to gather clinical utility and health economic data on the test.
360Dx Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.